Resources

Guidelines

Guidelines present relevant evidence to help physicians weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be essential in everyday clinical decision-making.

Visit here

Susan Dent from ASCO Daily News:

How to Optimize Cardiovascular Health in Patients With Cancer and Survivors.

Description of cardio-oncology program

The field of cardio-oncology has emerged in response to the need to provide the best cancer care without compromising cardiovascular health. Here are some resources designed to help you understand .

Moffit Cancer Center, Tampa, FL

Moffitt Cancer Center’s Cardio-Oncology Program helps patients monitor and manage the cardiovascular side effects of cancer treatment, as well as pre-existing cardiovascular conditions that might complicate a patient’s diagnosis. We are the first such academic program in the region, bringing together the expertise of researchers and oncologists from Moffitt and expert cardiologists from USF Health.
Our Cardio-Oncology Program welcomes any patient actively receiving cancer therapy, as well as survivors who have completed treatment. Certain therapies may lead to cardiovascular complications, which may occur long after the cancer treatments have ended.

Training and Education

An Overview of Cardio Oncology
Washington University, St. Louis
The survival of patients with cancer has dramatically improved over the past 30 years with the introduction of new therapeutic agents. As a result, there is an impressive increase in the number of cancer survivors and it is expected that there will be over 18 million in the US by the year 2020. A growing array of complex new therapies allows for even better overall outcomes for patients being treated for cancer. However, these therapies do not come without toxicities and cardiovascular structures can frequently become involved.
In the coming years there will probably be a Cardio-Oncology ‘epidemic’ due to either the growing population of cancer survivors, the increasing number of patients aged over 65 who need chronic cancer therapy and the high frequency of cancer therapy induced CVDs in these populations.
ESC Cardio-Oncology Council
The Cardio-Oncology Pharmacist's Network
This guideline, authored by a pan-Canadian expert group of health care providers and commissioned by the Canadian Cardiovascular Society, is intended to guide the care of cancer patients with established cardiovascular disease or those at risk of experiencing toxicities related to cancer treatment.

European Society of Cardiology webinar on use of MyoStrain in detecting and managing cardiac toxicity

Abstracts From GCOS 2019
The GCOS Clinical Practice Guidelines, prepared and reviewed by leading experts and based on the findings of evidence-based medicine, provide you with a set of recommendations to help patients with the best care options.
Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual survival of the patient with cancer.Recommendations were developed by an expert panel with multidisciplinary representation using a systematic review (1996 to 2016) .

Guidelines and Scientific Documents

Guidelines present relevant evidence to help physicians weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be essential in everyday clinical decision-making.

Most Recent Guidelines

Cardio-Oncology in 2019 Grand Rounds Mount Sinai Hospital Dr. Gagan Sahni

Houston Methodist Cardio-Oncology Program Update (BARRY TRACHTENBERG, MD) December 21, 2017

American College of Cardiology

By publishing the most impactful original research and state-of-the-art review articles pertaining to cardio-oncology.

European Society of Cardiology

In spring 2017 we had the idea to move forward and founded a group inside the ESC on Cardio-Oncology, it was decided to officially ask the constitution of an ESC Council of Cardio-Oncology.

Discusses Essentials of Cardio-Oncology

In this episode of the Heart podcast, Digital Media Editor, Dr James Rudd, is joined by Dr Arjun Ghosh from Bart’s Hospital in London.

Cancer treatments

Cancer treatments & cardiovascular toxicity 2016 (Position Paper)

European Association of Cardiovascular

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Prevention and Monitoring of Cardiac Dysfunction

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

Table of Cancer Therapies & Related Complications

Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations.

Improving Cardiovascular Outcomes

Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial.

Breast Cancer and Cardiovascular Disease

CVD in Patients and Survivors of Breast Cancer
  • In older, postmenopausal women, the risk of mortality attributable to CVD is higher in breast cancer survivors than in women without a history of breast cancer. This greater risk manifests itself approximately 7 years after the diagnosis of breast cancer.
  • Age-adjusted mortality rates of coronary heart disease (CHD) and stroke are higher than that of breast cancer.

New JACC: CardioOncology Video Case Presentation on Trastuzumab Cardiotoxicity
  • Editor-in-Chief Dr. Bonnie Ky, Deputy Editor Dr. Daniel Lenihan MD, Dr. Srilakshmi Vallabhaneni and Dr. Giuseppe Curigliano discuss a case of trastuzumab cardiotoxicity.

Cardiovascular Disease and Breast Cancer

Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.

Breast Cancer Therapy

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

MANTICORE 101-Breast

Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast).

For Patients

Cancer patients and cancer survivors may face an increased risk of heart and vascular disease.

For Providers

Cardio-oncology is the evolving discipline focused on the intersection of cardiovascular disease and cancer./h6>

Resources in Spanish

Suggested Readings in Cardio-Oncology

GUIDELINE AND POSITION STATEMENTS

Clinical Topics in Cardio Oncology

The goal of the COMPASS trial was to evaluate anticoagulation strategies with rivaroxaban among patients with stable atherosclerosis.

Recent Member Publications

Member Publications

A meta-analysis of efficacy of new oral anticoagulants in treatment of acute thromboembolic events in cancer patients.” by Sebastian Szmit, MD PhD

Member Publications

Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer” by Magdalena Zaborowska-Szmit, MD and Sebastian Szmit, MD PhD

New Patient Information Resource

Contact me if you like to use for yourself

How COVID-19 Is Affecting Cancer Care

The View From Italy

]

Giuseppe Curigliano, MD, PhD, of the University of Milan, talks about how, in the face of the coronavirus pandemic, he and his fellow oncologists have altered the way they treat patients with cancer. Filmed March 24, 2020.

 

Learn more

Meet The First Class of certified<br /> Cardio-Oncologists

On March 28, 2020 the individuals below successfully past our first Certification Exam in Cardio-Oncology.

Learn more